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Abstract
The growing prevalence rate of pediatric obesity, which is frequently accompanied by several cardiometabolic risk
factors, has become a serious global health issue. To date, little is known regarding differences for cardiometabolic
risk factors (prevalence and means) in children from different countries. In the present review, we aimed to provide
a review for the available evidence regarding cardiometabolic risk factors in overweight pediatric populations. We
therefore provided information with respect to the prevalence of impaired fasting glucose/impaired glucose
tolerance, high triglycerides, low HDL-cholesterol and hypertension (components of the metabolic syndrome)
among cohorts from different countries. Moreover, we aimed to compare the means of glucose and lipid levels
(triglycerides and HDL-cholesterol) and systolic/diastolic blood pressure values. After careful selection of articles
describing cohorts with comparable age and sex, it was shown that both prevalence rates and mean values of
cardiometabolic risk factors varied largely among cohorts of overweight children. After ranking for high/low means
for each cardiometabolic risk parameter, Dutch-Turkish children and children from Turkey, Hungary, Greece,
Germany and Poland were in the tertile with the most unfavorable risk factor profile overall. In contrast, cohorts
from Norway, Japan, Belgium, France and the Dominican Republic were in the tertile with most favorable risk
profile. These results should be taken with caution, given the heterogeneity of the relatively small, mostly clinical
cohorts and the lack of information concerning the influence of the values of risk parameters on true
cardiometabolic outcome measures in comparable cohorts. The results of our review present a fair estimation of
the true differences between cardiometabolic risk profiles among pediatric cohorts worldwide, based on available
literature.
Introduction
The ongoing global rise in the prevalence of overweight
and obesity among all age and ethnic groups is accom-
panied by a higher incidence in serious health risks,
such as type 2 diabetes (T2DM), and the development
of cardiovascular damage, which is already potentially
present at an early age.[1-3] In both children and adults,
detection of the metabolic syndrome, which encloses a
clustering of cardiometabolic disorders (i.e. central obe-
sity, disorders in glucose regulation, dyslipidemia and
hypertension) is a tool to identify individuals with high
risk on future T2DM and cardiovascular disease (CVD).
[4-6] However, no validated definition with standardized
cut-off values of the metabolic syndrome is available in
children, and as a consequence, many derivatives from
adult the metabolic syndrome-definitions are used to
attempt to implement the metabolic syndrome in pedia-
trics.[7-10] Therefore, a wide range of prevalence rates
of the metabolic syndrome among pediatric cohorts has
been reported, making it impossible to draw conclusions
with respect to differences between cohorts from differ-
ent countries. To overcome this issue in the present
review, description and comparison of the prevalence of
single cardiometabolic risk factors (the metabolic syn-
drome-criteria; impaired fasting glucose (IFG)/impaired
glucose tolerance (IGT), low HDL-cholesterol, high tri-
glycerides and hypertension) was performed.
Although it is difficult to standardize data from differ-
ent studies regarding age and BMI, we embarked on
this study to identify potential early trends with respect
to cardiometabolic variables between children from dif-
ferent countries. The premise of this review was to
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drome features, assuming that the risk for future CVD
conferred by the metabolic syndrome in adults is pro-
portioned to the number of the metabolic syndrome fea-
tures present. Moreover, mean values of aforementioned
variables between different countries can be compared
and used to estimate cardiometabolic risk. In the pre-
sent review, we performed a systematic literature search,
and aimed to provide an overview of available studies
reporting data regarding cardiometabolic risk factors in
pediatric cohorts with different ethnicities and
nationalities.
Methods
Prevalence/mean values of cardiometabolic risk factors
Information was collected regarding the prevalence and
means of the features of the metabolic syndrome
(impaired fasting glucose (IFG), impaired glucose toler-
ance (IGT), low HDL-cholesterol, high triglycerides and
high blood pressure).[9] Therefore, we searched
PubMed, EMBASE and the COCHRANE library for stu-
dies investigating the metabolic syndrome in youth
using the MeSH terms: ‘Overweight’, ‘Obesity’, ‘Meta-
bolic Syndrome X’, ‘Prevalence’, with limitation to stu-
dies in humans which have been published in English
and in an age range of 0-18 years. Figure 1a depicts the
flowchart showing the study inclusion steps. One inde-
pendent reviewer (MvV) selected all studies which
included more than 50 children (in a wider age range, i.
e. the cohort had to consist of both prepubertal and
pubertal children) and which reported information on
multiple outcome measures, being reported in either
mean values or prevalence numbers.
Data extraction
Figure 1 shows the literature search, which was carried
out from April to August 2009. This search was per-
formed by the first author and a clinical librarian, spe-
cialised in systematic search strategies. The selection
procedure was performed by the first author. Studies
which were classified as non-eligible were studies with
unrelated topics or in languages other than English, stu-
dies among older age groups (>20 years), reviews, and
studies that did not assess (components of) the meta-
bolic syndrome. After retrieval of 29 possible eligible
studies, 13 more were excluded due to study design
(population studies) or small cohorts (n<100), and a
total of 16 studies could be included in the present
review.
Assessment of prevalence numbers
To overcome the use of different cut-off values for the
cardiometabolic risk factors, we derived new prevalence
rates (high triglycerides above the 95
th percentile for age
and sex (>p95), low HDL-cholesterol <1.03 mmol/L and
hypertension >p95) from the reported prevalence rates.
This was performed with use of a reference group, from
which the distribution of prevalence rates for different
cut-off values was derived. The reference group con-
sisted of the data from Dutch native children from our
own multi-ethnic cohort (3-18 yrs, n = 262), and was
compared with the distribution of the prevalence rates
from the other ethnic groups. The formentioned cut-off
values were chosen in order to minimize the number of
estimated values. Ratios between prevalence numbers
from the old and new cut-off values in the reference
population were used to estimate the prevalence in the
cohort of interest. Since the distribution of prevalence
rates using different cut-off values was equal over all
ethnic groups within the reference cohort, it was
assumed that this also applied for the other study
cohorts.
Assessment of mean values and statistical analysis
In thirteen papers, data for means and standard devia-
tions (SD’s) with regard to cardiometabolic parameters
were available. In three articles, one or more parameters
were reported as median (range) or median (interquar-
tile range, IQR). When median values (range, or IQR)
were provided, the SD was estimated according to a pre-
viously validated method, in which the mean and var-
iance were estimated using simple formulas which
included the range and median.[11] To obtain differ-
ences between other populations and the Dutch
Figure 1 Literature search.
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estimating the standard error of the mean difference for
each comparison (using the SD and N), as recently
described.[12] Differences between different ethnic
groups as derived from the reference population were
tested with ANOVA and Bonferoni analysis (Dutch-
Turkish, Dutch-Moroccan and Dutch-Other groups).
Ranking
In order to produce a rough estimation of overall cardi-
ometabolic risk profile for each study cohort, mean
values of each country were ranked from highest to low-
est presumed cardiometabolic risk (or from lowest to
highest in case of HDL-cholesterol). Subsequently, an
overall rank was adopted from these separate rank
scores and the outcome was divided into tertiles. Since
it was found that elevation of systolic blood pressure
predicts the metabolic syndrome and hypertension in
later life best (with consequently higher risk for T2DM
and CVD), we decided to include only the systolic blood
pressure ranks in the analysis.[13]
Results
Characteristics of included studies
Characteristics of studies are shown in Table 1. Most
studies were performed in a clinical setting, however,
four were identified as population studies, but could be
included in the analysis due to a sufficient number and
separate analysis of overweight children. All studies
were cross-sectional in nature.
Both studies by Allemand et al.[14] (Central Europe)
a n dL ie ta l .[ 1 5 ]( C h i n a )p r o v i d e dn oi n f o r m a t i o nw i t h
regard to methods of measuring height and blood pres-
sure. All other studies reported resting blood pressure
values or average of three separate measurements while
seated. Information regarding the method of height
measurements (i.e. use of stadiometer) were lacking in
the studies by Bealoye et al. [16] (Belgium), Islam et al.
[17] (Japan), Dhuper et al. [18] (USA), Reinehr et al.
[19] (Germany) and Sen et al. [20] (Turkey).
Variation of prevalence rates across countries
Figure 2 shows the prevalence of cardiometabolic risk
factors according to different countries. Whereas the
prevalence of impaired fasting glucose (≥5.6 mmol/L)
was very low among pediatric cohorts in Southern Eur-
opean countries (1.0 to 4.6%), the USA (3.6-4.6%) and
Dominican republic (5%), the prevalence rate in the
Netherlands (especially among Dutch-Turkish and-Mor-
occan children) was remarkably high; 13.4% and 26.8%,
respectively. IGT varied from 1.3% (Dutch-Moroccan
children) to 6.5% in Central Europe. Similar prevalence
rates for IGT were found in Turkish children and
Dutch-Turkish children. Regarding lipid profiles,
children from Germany least frequently showed low
HDL-cholesterol (8.8%), while a high percentage of chil-
dren from rural USA presented with this lipid anomaly
(57%). High triglycerides were most prevalent in Ger-
many (52.7%) whereas prevalence rates varied in the
other countries from 12.3% to 35.9%. Finally, the pre-
sence of elevated blood pressure varied from 8.8% in
Italy, to 40.6% among children from Hungary.
Variation of mean values of cardiometabolic risk
parameters
Figure 3 shows a large variation for mean values of the
cardiometabolic variables per country. Fasting glucose
levels varied from 4.5 to 5.3 mmol/L (in France and
Turkey, respectively). The mean value of HDL-choles-
terol ranged from 1.1 mmol/L in Dutch-Turkish chil-
dren, and cohorts from the USA, Italy and Dominican
republic, to 1.4 mmol/L in Japan. Triglyceride levels
were highest in Hungary and Turkey (respectively 1.5
and 1.6 mmol/L), while mean BMI of these cohorts did
not exceed 30 kg/m
2. Systolic blood pressure was gener-
ally highest in countries from which cohorts exceeded
30 kg/m
2, with a value of 121 mmHg (Poland) to 126
mmHg (Hungary). Children in the Dominican Republic
showed the lowest mean value of systolic blood pres-
sure, despite their mean BMI of 34 kg/m
2.
Overall cardiometabolic risk
Table 2 shows the ranking of countries per cardiometa-
bolic parameter and overall cardiometabolic risk profile
rank. Children from Hungary, Greece, Germany, and
Poland, as well as Dutch-Turkish children were in the
tertile with the most unfavorable cardiometabolic risk
profile. In contrast, children from Norway, China, Bel-
gium, France and Dominican Republic together made
up the tertile with the presumably most favorable cardi-
ometabolic risk profile, while the mean BMI of the
cohort in Belgium and the Dominican Republic still
exceeded 30 kg/m
2. Contradictive results were derived
from the two studies from Italy and two studies from
Turkey, from which one cohort in each country was
classified as having a favorable cardiometabolic risk pro-
file, while the other was assigned an unfavorable cardio-
metabolic risk rank.
Discussion
The present review showed a large variation for preva-
lence rates and mean values of cardiometabolic risk
parameters among children according to country of ori-
gin, and reveals several interesting findings. In summary,
children from Norway, China, Belgium, France and the
Dominican Republic constitute the tertile with the most
favorable values of cardiometabolic risk parameters. In
contrast, children from Central and Eastern Europe
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Europe (Hungary, Greece) and Turkey constitute the
third of children with the most adverse values of cardio-
metabolic risk parameters. The former is in line with
the finding that mortality rates from CVD are generally
higher in Central and Eastern Europe than in Northern,
Southern and Western Europe, as concluded by a report
concerning cardiovascular disease statistics.[21]
Some of the comparisons between cohorts from differ-
ent countries have been studied before, however, most stu-
dies originate from the United States, with the focus on
differences between the white, black and Hispanic popula-
tion. Therefore, the cardiometabolic differences between
black and white children living in the USA are well-known
(i.e. a more favorable lipid profile and slightly higher
prevalence of hypertension.[7,22-26] Our review supports
this finding, and adds that this difference is also found
between black children and other cohorts, however, chil-
dren from Greece and Hungary present with similar blood
pressure values as the cohort of children of mainly Afri-
can-American descent. Although some differences may be
explained by characteristics of the cohort (i.e. more obese),
others cannot. In example, high triglycerides and high
blood pressure were quite lowi na nI t a l i a n ,e x t r e m e l y
obese cohort, while they were frequently present in a mod-
erately obese German cohort, and in a cohort from Cen-
tral Europe (Germany/Switzerland/Austria).[14,27]
Therefore, it is presumed that genetic profile and dietary
habits play a substantial role outside the degree of obesity
in affecting cardiometabolic risk parameters.
Table 1 Study characteristics of included studies for comparison of prevalence numbers/means
Country Author
Ref N Patient characteristics Study nature Data BMI (kg/m
2)/Z-
BMI
The Netherlands Van Vliet et al.
[34]
95 Dutch native, Turkish, Moroccan and
Other subgroups, 3-18y
Clinical Prevalence/
mean
27.7 ± 5.9/2.8 ±
0.5
Italy
1 Invitti et al.[27] 588 6-16y Clinical Prevalence/
mean
33.9 ± 5.5
France Druet et al.[36] 308 7-17y Clinical Prevalence/
mean
28 (24.4-32.3)
Spain Lopez-Capape
et al.[37]
429 4-18y Caucasian and Hispanic Clinical Prevalence/
mean
27.3 ± 3.5
Turkey
1 Atabek et al.
[38]
169 7-18y Clinical Prevalence/
mean
27.2 ± 3.6
Turkey
2 Sen et al.[20] 352 2-19y Clinical Prevalence/
mean
29.1 ± 4.3
USA Dhuper et al.
[18]
576 3-19y, mainly black cohort Population Prevalence/
mean
33.2 ± 7.6
USA Davis et al.[39] 102 7-18y, rural Georgia, black and white
mixed
Population Prevalence/
mean
27.6 ± 5.2
Dominican Republic Sherry et al.[40] 193 2-20y Clinical Prevalence/
mean
31.3/2.6
Germany Reinehr et al.
[19]
463 4-17y Clinical? Prevalence/
mean
27.1 (24.5-29.9)/
2.36
Central Europe (Germany/
Switserland/Austria)
Allemand et al.
[14]
25473 1-20y Clinical Prevalence >29.4/2.32
Norway Kolsgaard et al.
[33]
120 Norwegian, native subgroup, 6-17y Clinical? mean 28.1 (25.5-31.0)/
2.1 ± 0.3
China Li et al.[41] 620 7-18 yrs Population mean >p85
Belgium Beauloye et al.
[16]
104 8-18 yrs Clinical mean 30.2 ± 0.5/2.8 ±
0.7
Japan Islam et al.[17] 471 7-15y Annual health
examination
Mean 25.7 ± 2.4
4.5-18.2y 25.7 ± 2.4
Poland, Greece, Italy
2, France,
Hungary
Bokor et al.[42] 90 Polish Clinical mean 30.8 ± 4.9
145 Greek 30.1 ± 4.9
274 Italian 26.8 ± 3.6
283 French 37.7 ± 5.9
449 Hungarian 31.1 ± 4.8
Data regarding BMI and Z-BMI are shown as mean ± SD or median (interquartile range)
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valence rates remains under debate. Despite varying
mean values amongst populations from different origins
or ethnic backgrounds, reference values suggested by
international guidelines are often applied, assuming a
linear relationship between mean values of cardiometa-
bolic parameters and actual cardiometabolic risk. How-
ever, it has been shown that not all populations have
similar baseline risk for CVD and therefore, ethnic-spe-
cific reference values are warranted. To illustrate, in
Mexico, an unusual high prevalence of low HDL-choles-
terol among non-overweight subjects was found, (NCEP
reference values), namely 83%.[28] Surprisingly, mortal-
ity from CVD among the Mexican population is lower
than among non-Hispanic whites.[29] Therefore, one
might argue that lower HDL-cholesterol levels among
Hispanics (as compared to whites) are acceptable and
do not lead to a higher mortality rate. In contrast, one
might hypothesize that interventions improving lipid
metabolism may lead to an even lower prevalence of
death from CVD.
A recent review reported a lower prevalence of lipid
disorders in black children as compared to white chil-
dren, and were less frequently diagnosed with the meta-
bolic syndrome as a consequence.[30] This finding is
contradictory to the finding that blacks are having more
frequently diabetes and CVD as compared to whites. To
overcome this discrepancy, the review suggested that
lipid reference values in black children should be more
strict, in order to achieve a prevalence of the metabolic
syndrome which would correspond better with actual
cardiometabolic outcome. Although the adjustment of
lipid levels reference values might in part accomplish
forementioned goal, probably hypertension and other
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Figure 2 Prevalence rates of cardiometabolic risk factors according to country. IFG is indicated by light grey bars, IGT by dark grey bars.
Blocked bars indicate a cohort with a BMI >30 kg/m
2.
ESEstimated prevalence from distribution in reference cohort. USA
rural Cohort from the
USA from rural area (both black and white children included). USA
black Cohort from the USA with predominantly black children. IFG-impaired
fasting glucose, IGT-impaired glucose tolerance, Dominican Rep-Dominican Republic.
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Page 5 of 9factors such as ox-LDL, hs-CRP and IL-6 (which are not
accounted for in the metabolic syndrome) may cause
the higher incidence of diabetes and CVD among
blacks.[31]
,[32] Therefore, in case of African-American
children, the use of stricter cut-off values for lipid levels
will probably not induce identification of those most at
risk for CVD. Further studies are needed to determine
the optimal reference values for cardiometabolic risk
parameters in specific populations.
Also within countries, large differences between means
for cardiometabolic risk parameters were found, which
limits extension of the outcome to the general popula-
tion. In example, cohorts from the two studies from
Italy (Milano, mean BMI 33.9 ± 5.5 and Rome, mean
BMI 26.8 ± 3.6, respectively), showed opposite cardio-
metabolic characteristics. While the cohort from Milano
(despite the higher mean BMI), was in the tertile with
the most favorable cardiometabolic risk profile, the
cohort from Rome was in the terile with the most
adverse cardiometabolic risk profile. Selection bias and
geographical location of both institutions (ie outskirts
vs. city center) may have accounted for the difference in
outcomes.
The difference between cardiometabolic risk profile
between the Turkish cohorts may be explained by differ-
ences in age range (2-19 vs. 7-18 yrs), confirming a
more adverse cardiometabolic risk profile in older chil-
dren. Interestingly, Dutch-Turkish children, (age range
3-18 yrs), presented with a similar risk profile as the
older cohort (7-18 yrs) from Turkey. Forementioned
findings thus indicate that Dutch-Turkish children have
a cardiometabolic risk profile which is even less favor-
able as compared to children living in Turkey.
Next to age and geographical location, varying BMI
may account for some of the differences found between
the studies. It would be expected that the cardiometa-
bolic risk parameters would be more favorable in similar
samples with lower BMI values. Although, in the present
review, the former statement was true for blood pres-
sure (highest among extremely obese subjects), this did
not apply to glucose levels, as they were lowest among
the extremely obese cohorts. Since we do not have data
from moderately obese children from the same country,
the meaning of this finding remains unclear, however it
might be hypothesised that in some cohorts, a favorable
genetic profile may preponderate over increasing BMI in
glucose regulation.
Few studies have been performed with regard to cardi-
ometabolic risk factors among children of ethnic descent
within countries. In a Norwegian study which compared
immigrants (Pakistani, Tami la n dT u r k i s h )t on a t i v e
Norwegian children, higher rates of insulin resistance
and the metabolic syndrome were found among immi-
grant subjects.[33] In a study performed among 516
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Figure 3 (continued) Mean values of cardiometabolic risk
variables according to country. Data are shown as mean ± SD
across countries. Means displayed as a triangle indicate cohorts with
a mean BMI between 25 and 30 kg/m
2. Means displayed as squares
indicate cohorts with a mean BMI>30 kg/m
2. For blood pressure,
both systolic (upper means and whiskers) and diastolic (lower
means and whiskers) are shown. *P<0.05 as compared to Dutch
native children.
ESMean and SD estimated from median (range or
interquartile range). Dominican Rep - Dominican Republic.
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Page 6 of 9multi-ethnic children in the Netherlands, the cardiome-
tabolic risk profile appeared more favorable in children
of Moroccan descent, and more adverse in children of
Turkish origin, as compared to Dutch native children.
This previous finding is partly confirmed by the results
of the present study, in which Turkish cohorts appear to
have high mean glucose and triglyceride levels (but also
high HDL-cholesterol).[34] It may be postulated that
immigration of Turkish children to the Netherlands has
an additional adverse effect on cardiometabolic risk pro-
file. This may be attributed to several reasons, among
which change of dietary habits and less physical
exercise.
One of the limitations of this review is the inclusion of
mainly studies of clinical nature, with small sample
sizes, which makes it hard to extend the individual
study outcomes to the general population of a specific
country. Despite careful selection of the studies, there
was still some heterogeneity among them, and small dif-
ferences between methods of blood pressure measure-
ments and measuring height could have in part
attributed to some the differences found. Moreover, data
with respect to the values of cardiometabolic parameters
in childhood and the actual cardiometabolic risk in
adulthood are scarce. A single study was performed
using mortality as primary end-point, and reported that
glucose intolerance, and hypertension (not high total
cholesterol) in childhood were strongly associated with
increased rates of premature death from endogenous
causes.[35] Due to aformentioned reasons, the outcome
of this review should be interpreted with caution; how-
ever, we believe that this review gives some insight and
a good overview of available studies on the subject of
cardiometabolic risk in childhood obesity.
In conclusion, among pediatric cohorts, consisting of
both pubertal and prepubertal children, a wide variation
of mean values for different cardiometabolic parameters
were found, with most favorable values in cohorts of
children from Norway, China, Belgium, France and the
Dominican Republic, and least favorable values in a
cohort of Dutch-Turkish children, as well as children
from cohorts from Germany, Poland, Hungary, Greece
and Turkey. These results should be taken with caution,
given the heterogeneity of the relatively small, mostly
clinical cohorts and the lack of information concerning
the influence of the values of risk parameters on true
cardiometabolic outcome measures in comparable
cohorts.
Table 2 Ranking countries for most adverse cardiometabolic risk factor profile
Country (ref) Mean BMI (kg/m
2) Mean glucose
rank
Mean triglyceride
rank
Mean
HDL-cholesterol
rank
Mean
systolic blood
pressure rank
Total
cardiometabolic risk rank
Hungary [42] 31.1 13 2 8 1 1
Dutch-Turkish [34] 29.3 2 13 1 9 2
Turkey
1 [38] 27.2 1 1 9 15 3
Italy
2 [42] 26.8 8 4 2 10 4
Greece [42] 30.1 4 4 18 3 5
Germany [19] 27.1 10 3 14 6 6
Poland [42] 30.8 13 8 9 4 7
Dutch-Other [34] 29.1 5 14 6 10 8
USA rural [39] 27.6 7 10 4 15 9
USA black [18] 33.2 19 12 4 4 10
Japan [17] 25.7 7 6 20 8 11
Dutch-native [34] 28.7 6 16 9 10 11
Turkey
2 [20] 29.1 7 7 18 10 13
Spain [37] 27.3 11 21 9 - 13-19
Dutch-Moroccan 28.4 2 19 7 15 14
France [36] 37.7 20 8 9 6 14
Dominican Republic [40] 34 13 11 2 18 16
Italy
1 [27] 33.9 20 17 9 2 17
China [41] - 13 17 16 - 17-19
Norway [33] 28.2 13 14 16 14 18
Belgium [16] 30.2 13 20 15 - 18-19
Ranking was performed according from highest to lowest mean value for each cardiometabolic risk parameter (lowest to highest in case of HDL-cholesterol).
Secondly, an overall mean rank was assigned to each cohort
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